Change in Sponsor

This trial is seeking to determine whether a single 4mg intranasal dose of bumetanide acutely reduces pulmonary artery pressure and blood volume in the outpatient setting for patients with heart failure and an implanted device for remote patient monitoring (i.e. Cordella or CardioMEMS).

Inclusion Criteria:

• Age ≥ 18 y with chronic HF (NYHA II-III).
• Successful CardioMEMS or Cordella implantation ≥ 3 months prior.
• Clinically mild or worse congestion (no IV diuretics within 7 days).
• eGFR ≥ 20 mL/min/1.73 m²; serum K⁺ 3.5-5.2 mmol/L.

Exclusion Criteria:

• SBP < 90 mmHg, HR < 50 bpm, or > 110 bpm at baseline.
• Acute HF hospitalization < 30 days.
• Chronic nasal pathology or recent intranasal surgery.
• Known allergy to bumetanide or sulfamides.
• Pregnancy or lactation.
• Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device which has not reached its primary endpoint.